Aragen Life Sciences operates as a contract research, development and manufacturing organization (CRDMO) offering end‑to‑end services from discovery through commercialization, including recent biologics and ADC capabilities. The company recently completed qualification of a biologics manufacturing facility, with first GMP batches scheduled for late July 2025 and the first phase having become operational in December 2024 to support Phase 2 trials and beyond. Aragen is expanding its India operations, announcing a planned ₹2,000 crore investment in Telangana that is expected to create 1,500 jobs. Management is pursuing both organic capacity expansion and selective acquisitions while pushing international market penetration. The firm is preparing for a potential IPO and has strategic financial backing from investors to support that path. Following a $100M investment from Quadria Capital that values the company at about $1.4B, Aragen has strengthened its position in the competitive CRDMO market and is positioning to capture growing biologics outsourcing demand. Aragen Life Sciences is a contract research organization and contract development and manufacturing organization offering outsourced discovery, development and manufacturing services across small- and large-molecule platforms. The company serves a worldwide customer base including the United States, Europe and Japan and has built deep domain expertise and strong global delivery capabilities. Aragen has demonstrated strong organic growth and partnerships with global biopharmaceutical and biotech clients. The business operates across seven sites in India and overseas, employs over 3,000 professionals, and serves more than 450 life-sciences customers. Recently the company sold a significant minority stake to Goldman Sachs through a purchase of shares held by ChrysCapital and other existing shareholders. Management and Goldman Sachs plan to expand Aragen’s portfolio of differentiated offerings and client base to accelerate growth and move toward becoming a leading global end-to-end drug discovery and development provider.

Total raised

$100M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2025